Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIM-NIVO: Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies
NCT03816345Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2019
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of nivolumab in malignant solid neoplasm and hematopoietic and lymphoid cell neoplasm (11 arms), sponsored by National Cancer Institute. Primary endpoints: Incidence of adverse events, Change in disease assessments and 4 more. Started Jul 2019; status: recruiting.
02
Drugs
03
Conditions
malignant solid neoplasmhematopoietic and lymphoid cell neoplasm
Beyond the preview
Go deeper on NCT03816345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03816345.